Issels Integrative Immuno-Oncology December 29, 2016  

Immunotherapy Creates Buzz in the World of Cancer Research Publications

Dear Friend,

Thanks to rapid and effective developments, immunotherapy for cancer continues to be a hot topic in the medical community. A recent analysis shows the explosive growth of this subject in academic and industrial publications.

Immunotherapy for Cancer in the News

Results of the analysis conducted by Drs. Enal Razvi and Gary Oosta were published in Genetic Engineering & Biotechnology News. Data was based on publications in the broad space of cancer immunology, which have seen exponential growth from zero in the early '70s to more than 600 in the past year.

While there has been a clear increase in quantity, what about qualitative measures? A word cloud corresponding to titles and abstracts shows that the major areas of focus are "cancer," "immunotherapy," "cells," "immune" and "tumor."

Drilling down to find the key components of these publications, the most commonly mentioned one is "dendritic cells," which play a vital role in initiating the immune response. "Cell death" (apoptosis) has generated 33 percent annual growth.

What Does the Future Hold?

Drs. Razvi and Oosta drew the following conclusions:

• Understanding in vivo mechanisms and pathways driving immunological cascades is crucial for continued progress.

• Companies will continue clinical trials, both individually and in collaboration with others.

Immunotherapy for cancer will eventually use biomarkers to identify which populations and sub-populations are the optimum candidates for specific treatments.

Individualized Blueprints for Immunotherapy

At Issels®, our integrative therapies are personalized based on each patient's lifestyle and genetic makeup as well as the tumor microenvironment. Contact us today to hear success stories from patients of all ages who have dealt with leukemia, melanoma and other forms of cancer.

Immunotherapy Creates Buzz in the World of Cancer Research Publications

Read more interesting articles on the "Issels Cancer Immunotherapy" news/blog posted every Tuesday and Thursday. Check It Out Now »

Does Treatment Cause Cancer to Spread?

A recent discovery by a team of Israeli scientists has shed new light on the problem. Their study involved mice with multiple myeloma, which is produced in bone marrow and spreads throughout the body. They received treatment with bortezomib, an anti-cancer drug with the brand name of Velcade.

The researchers were surprised to find that Velcade caused inflammatory cells in the bone marrow to accelerate the cancer, arming the cells with resistant properties. While they emphasize that “treatment with Velcade is essential and necessary,” the team is working on methods to inhibit the body’s response so treatments are more effective.

Get the Full Story!

Research Being Done to Boost Immunotherapy Response in the Tumor Microenvironment

A team at the University of Pittsburgh conducted a study to determine why treated T cells lose mitochondrial function once they are reintroduced to the tumor environment.

They confirmed that the reaction is definitely a result of proximity to the tumor and not a side effect of activation. Data obtained during testing showed that the tumor microenvironment contains signals that repress oxidative metabolism in T cells. In effect, the cells starve from lack of energy.

Get the Full Story!

Videos – What Do Patients Say About Their Experience?

Watch videos of patients who share their own experiences at the Issels clinics with you. Listen to their stories and cancer journeys.

Get the Full Story!

Learn More

Testimonials »

Treatments »

Vaccines »

Statistics »

History »

Locations »

Contact Us »

Connect With Us:

Google +

Contact Info:

Phone: 888-447-7357


Treatments | Testimonials | Contact Us